

Doxycycline Plus Streptomycin Versus Ciprofloxacin Plus Rifampicin in Spinal Brucellosis

Submission date	Recruitment status	<input type="checkbox"/> Prospectively registered
22/03/2006	No longer recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
29/03/2006	Completed	<input checked="" type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
13/10/2009	Infections and Infestations	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Emine Alp

Contact details

Department of Infectious Disease

Erciyes University Medical School

Kayseri

Türkiye

38039

ealp@erciyes.edu.tr

Additional identifiers

Protocol serial number

04/131

Study information

Scientific Title

Study objectives

Ciprofloxacin plus rifampicin may be an alternative treatment regimen to doxycycline plus streptomycin in the treatment of spinal brucellosis

Ethics approval required

Old ethics approval format

Ethics approval(s)

Yes, Approved by the Ethical Committee of Erciyes University, approval date: 4/05/2001, reference number: 04/131

Study design

An open, controlled and non-randomized trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Brucellosis is an infectious disease affecting multiple systems including vertebrae

Interventions

To compare the efficacy, adverse drug reactions, complications and cost of ciprofloxacin plus rifampicin versus doxycycline plus streptomycin in the treatment of spinal brucellosis

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Doxycycline, streptomycin, ciprofloxacin, rifampicin

Primary outcome(s)

1. Clinical efficacy of ciprofloxacin plus rifampicin in spinal brucellosis
2. The prevalence of relapses

Key secondary outcome(s)

The cost of the two regimens

Completion date

31/12/2004

Eligibility

Key inclusion criteria

The patients diagnosed with spinal brucellosis between January 2002 to December 2004 were enrolled into two study groups consecutively

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Age less than 16 years
2. Pregnancy
3. Neurobrucellosis
4. Previous history of brucellosis and antimicrobial therapy and discontinuation of the therapy for any reason (allergy to any of the drugs, death, adverse reactions)

Date of first enrolment

01/01/2002

Date of final enrolment

31/12/2004

Locations

Countries of recruitment

Türkiye

Study participating centre

Department of Infectious Disease

Kayseri

Türkiye

38039

Sponsor information

Organisation

Erciyes University Medical School (Turkey)

ROR

<https://ror.org/047g8vk19>

Funder(s)

Funder type

University/education

Funder Name

The study was supported by Infectious Disease Clinic, Erciyes University Medical School (Turkey)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	11/04/2006		Yes	No